Quick Answer
Tvardi Therapeutics, Inc. reported Revenue (ASC 606) of $7.14 million for fiscal year 2024.
Tvardi Therapeutics, Inc. Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2024 | $7.14M | -66.0% |
| 2023 | $20.97M | -49.9% |
| 2022 | $41.87M | +81.8% |
| 2021 | $23.03M | -83.0% |
| 2020 | $135.08M | +579.3% |
| 2019 | $19.89M | +47.6% |
| 2018 | $13.47M | +1378.5% |
| 2017 | $911.0K | +959.3% |
| 2016 | $86.0K | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| March 31, 2025 | $2.57M | +20.3% | +0.5% |
| September 30, 2024 | $2.56M | -47.5% | +157.9% |
| June 30, 2024 | $991.0K | -85.7% | -53.6% |
| March 31, 2024 | $2.13M | -65.4% | -56.1% |
| September 30, 2023 | $4.87M | -55.0% | -29.8% |
| June 30, 2023 | $6.93M | -69.9% | +12.5% |
| March 31, 2023 | $6.17M | +28.7% | -43.0% |
| September 30, 2022 | $10.81M | -46.7% | -53.0% |
- Tvardi Therapeutics, Inc. showed a decrease of -66.0% in Revenue (ASC 606) compared to the prior fiscal year.
- Over the 2016–2024 period, Tvardi Therapeutics, Inc.’s revenue (asc 606) has grown by 8198.8% (from $86.0 thousand to $7.14 million).
- The most recent figure is from Tvardi Therapeutics, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on March 11, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: